Detect biomarkers associated with nonalcoholic fatty liver disease (NAFLD)
Detect biomarkers associated with nonalcoholic fatty liver disease (NAFLD)
Abstract
In this 1-hour discussion, learn how the SomaScan® Assay can be used to detect biomarkers associated with NAFLD—specifically, the identification of circulating proteins associated with fibrosis in NAFLD using a custom 5k-plex SomaScan Assay. Also discussed is the importance of identifying non-invasive biomarkers that improve clinical decision-making and drug development for NAFLD, and the strategies for multiplexed validation of candidate biomarkers discovered using the SomaScan Assay.
Kathleen Corey, MD, MPH, MMSc
Director of the Massachusetts General Hospital NAFLD program and an Assistant Professor of Medicine at Harvard Medical School
Rebecca Pitts
Principal scientist at the Novartis Institutes for BioMedical Research in Cambridge, Massachusetts
Detect biomarkers associated with nonalcoholic fatty liver disease (NAFLD)
A webinar presented by Kathleen Corey, MD, MPH, MMSc, and Rebecca Pitts
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.